Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 3
2007 4
2008 6
2009 3
2010 5
2011 4
2013 4
2014 9
2015 11
2016 12
2017 12
2018 8
2019 19
2020 33
2021 19
Text availability
Article attribute
Article type
Publication date

Search Results

135 results
Results by year
Filters applied: . Clear all
Page 1
The PD-1/PD-Ls pathway and autoimmune diseases.
Dai S, Jia R, Zhang X, Fang Q, Huang L. Dai S, et al. Among authors: jia r. Cell Immunol. 2014 Jul;290(1):72-9. doi: 10.1016/j.cellimm.2014.05.006. Epub 2014 May 27. Cell Immunol. 2014. PMID: 24908630 Review.
Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.
Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, Zhang G, Zhao C, Zhang Y, Chen C, Wang Y, Yi X, Hu Z, Zou J, Wang Q. Xu J, et al. Among authors: jia r. Clin Cancer Res. 2019 Jan 15;25(2):515-523. doi: 10.1158/1078-0432.CCR-18-2484. Epub 2018 Oct 22. Clin Cancer Res. 2019. PMID: 30348638 Free article. Clinical Trial.
Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
Sun B, Yang D, Dai H, Liu X, Jia R, Cui X, Li W, Cai C, Xu J, Zhao X. Sun B, et al. Among authors: jia r. Cancer Immunol Res. 2019 Nov;7(11):1813-1823. doi: 10.1158/2326-6066.CIR-19-0026. Epub 2019 Sep 4. Cancer Immunol Res. 2019. PMID: 31484657 Free article.
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, Li Z, Xu N, Li E, Liu T, Bai Y, Yuan Y, Li X, Wang X, Chen J, Ying J, Yu X, Qin S, Yuan X, Zhang T, Deng Y, Xiu D, Cheng Y, Tao M, Jia R, Wang W, Li J, Fan S, Peng M, Su W. Xu J, et al. Among authors: jia r. Lancet Oncol. 2020 Nov;21(11):1500-1512. doi: 10.1016/S1470-2045(20)30496-4. Epub 2020 Sep 20. Lancet Oncol. 2020. PMID: 32966811 Clinical Trial.
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.
Xu J, Shen L, Bai C, Wang W, Li J, Yu X, Li Z, Li E, Yuan X, Chi Y, Yin Y, Lou W, Xu N, Bai Y, Zhang T, Xiu D, Wang X, Yuan Y, Chen J, Qin S, Jia R, Lu M, Cheng Y, Zhou Z, Li J, He J, Su W. Xu J, et al. Among authors: jia r. Lancet Oncol. 2020 Nov;21(11):1489-1499. doi: 10.1016/S1470-2045(20)30493-9. Epub 2020 Sep 20. Lancet Oncol. 2020. PMID: 32966810 Clinical Trial.
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.
Xu J, Li J, Bai C, Xu N, Zhou Z, Li Z, Zhou C, Jia R, Lu M, Cheng Y, Mao C, Wang W, Cheng K, Su C, Hua Y, Qi C, Li J, Wang W, Li K, Sun Q, Ren Y, Su W. Xu J, et al. Among authors: jia r. Clin Cancer Res. 2019 Jun 15;25(12):3486-3494. doi: 10.1158/1078-0432.CCR-18-2994. Epub 2019 Mar 4. Clin Cancer Res. 2019. PMID: 30833272 Free article. Clinical Trial.
A Reconfigurable Remotely Epitaxial VO2 Electrical Heterostructure.
Guo Y, Sun X, Jiang J, Wang B, Chen X, Yin X, Qi W, Gao L, Zhang L, Lu Z, Jia R, Pendse S, Hu Y, Chen Z, Wertz E, Gall D, Feng J, Lu TM, Shi J. Guo Y, et al. Among authors: jia r. Nano Lett. 2020 Jan 8;20(1):33-42. doi: 10.1021/acs.nanolett.9b02696. Epub 2019 Dec 4. Nano Lett. 2020. PMID: 31769995
135 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page